Market Overview

UPDATE: Third Point Addresses Sotheby's Adoption of a Poison Pill – A Relic from the 1980's

Related BID
'Ongoing Modern Transformation' Gets Sotheby's A Cowen Upgrade
Does A Top Christie's Contemporary Art Exec Leaving Open The Door For Sotheby's?
Atlassian Q2 Revenue Tops Views, But Q3 Earnings Guidance Misses (Investor's Business Daily)

Third Point is disappointed that Sotheby's (NYSE: BID) Board of Directors has trotted out the poison pill – a relic from the 1980's – as its disproportionate response to the valid concerns expressed in our October 2^nd letter. Rather than address our well-documented citations of mismanagement and initiate a constructive dialogue with its largest shareholder, the Board and the CEO have attempted to further entrench themselves.

Third Point's involvement does not pose a threat to either the Company or our fellow shareholders, all of whom will benefit from our considerable efforts. It is clear that today, the Chief Executive Officer and his hand-picked directors have put their job security ahead of shareholders.

Given their personal interests and miniscule shareholdings of Sotheby's, the Board's actions – disenfranchising its owners who may wish to acquire a more significant stake – come as no surprise. We hope this will be the Ruprecht Board's final snub to its shareholders. It would be unfortunate if they instead refuse to undertake a fresh start until one is imposed upon them during proxy season.

About Third Point LLC: Third Point LLC is an SEC-registered investment adviser headquartered in New York. Third Point is Sotheby's largest shareholder with a 9.3% stake in the Company's outstanding shares. Founded in 1995, Third Point follows an event-driven approach to investing globally. Third Point manages assets for Third Point Reinsurance Limited (NYSE: TPRE) and Third Point Offshore Investors Limited (LSE:TPOU LN), as well as its private funds.

Posted-In: News Hedge Funds General


Related Articles (BID + TPRE)

View Comments and Join the Discussion!